Mission Statement, Vision, & Core Values of Ovid Therapeutics Inc. (OVID)

Ever wondered what drives a biopharmaceutical company dedicated to developing treatments for brain conditions? What are the guiding principles behind their quest to conquer seizures? Let's delve into the mission, vision, and core values that shape the strategic direction of a company focused on addressing significant unmet needs in neurotherapeutics, especially considering that nearly 50 million people worldwide live with epilepsies and seizures.

How do these elements translate into tangible actions, especially when the company reported full-year 2024 revenues of $566,000 and a net loss of $26.4 million ($0.37 per share)? Are you curious to know how they balance their commitment to serving patient communities with the financial realities of drug development?

Read on to explore the foundational statements that steer this company's path in the complex world of neurological drug development, particularly as they advance a pipeline of small molecule medicines and manage a cash runway expected to support operations into the second half of 2026, with $53.1 million in cash, cash equivalents, and marketable securities as of December 31, 2024.

Ovid Therapeutics Inc. (OVID) An Overview of

Ovid Therapeutics Inc. (OVID) is a biopharmaceutical company committed to developing impactful medicines for patients and families affected by rare neurological diseases. While specific, up-to-the-minute sales figures for April 2025 are unavailable, Ovid's focus remains on advancing its pipeline and bringing innovative therapies to market. You can find more information on Ovid Therapeutics Inc. (OVID) Investor Profile here: Exploring Ovid Therapeutics Inc. (OVID) Investor Profile: Who’s Buying and Why?

As a company focused on rare neurological diseases, Ovid Therapeutics' financial performance is closely tied to the progress of its clinical trials and the potential approval and commercialization of its drug candidates. While real-time financial data for April 2025 isn't accessible, information from their latest financial reports, typically available on their investor relations page or through financial news outlets, would provide insights into their revenue, expenses, and overall financial health. Keep an eye on these resources for the most current financial details.

Ovid Therapeutics operates within a competitive landscape of pharmaceutical and biotechnology companies, all striving to address unmet medical needs. Ovid distinguishes itself through its specific focus on rare neurological disorders. To delve deeper into the factors that underpin Ovid's achievements and strategic approach, continue reading to explore their mission, vision, and core values.

Ovid Therapeutics Inc. (OVID) Mission Statement

Ovid Therapeutics Inc. (OVID) focuses on developing impactful medicines for rare neurological disorders. The company's mission is centered around patients, science, and innovation, aiming to address unmet needs in the treatment of conditions like Angelman syndrome and other rare epilepsies. Ovid's approach involves rigorous research and clinical development to deliver therapies that can significantly improve the lives of individuals and families affected by these disorders.

Ovid Therapeutics’ mission statement reflects a commitment to:

• Patients: Prioritizing the needs and well-being of patients with rare neurological disorders.
• Science: Employing cutting-edge research and scientific methodologies to develop effective treatments.
• Innovation: Fostering a culture of innovation to create novel therapies that address unmet medical needs.

Ovid Therapeutics is dedicated to its mission of transforming the lives of people with rare neurological disorders through innovative and impactful medicines. More information about Ovid and its pipeline can be found on their website.

Ovid Therapeutics reported a net loss of $39.8 million, or $0.68 per share, for the year ended December 31, 2024. Research and development expenses were $27.9 million for the same period, reflecting the company's ongoing investment in its pipeline of novel therapies for rare neurological disorders. Exploring Ovid Therapeutics Inc. (OVID) Investor Profile: Who’s Buying and Why?

Ovid Therapeutics Inc. (OVID) Vision Statement of

As of April 2025, understanding Ovid Therapeutics' vision requires a dive into its goals, mission, and the values that guide the company. While a specific, publicly declared vision statement for Ovid Therapeutics isn't available, we can infer their strategic direction from their public statements and activities, particularly focusing on their mission and core values. Ovid Therapeutics Inc., a biopharmaceutical company, is dedicated to developing impactful medicines for rare neurological disorders. To gain a better understanding of Ovid Therapeutics Inc., explore Ovid Therapeutics Inc. (OVID): History, Ownership, Mission, How It Works & Makes Money.

Ovid Therapeutics focuses on developing therapies for rare neurological disorders. In 2024, their pipeline and research programs are geared towards addressing conditions with significant unmet needs. Their approach involves:

• Targeting Specific Genetic Mutations: Identifying and developing treatments for disorders caused by specific genetic mutations.
• Novel Therapeutic Approaches: Exploring innovative methods to modulate neuronal function and improve patient outcomes.
• Clinical Trials: Conducting rigorous clinical trials to assess the safety and efficacy of their drug candidates.

In alignment with their goals, Ovid states that their mission is to:

• Develop medicines that transform the lives of people with rare neurological diseases.

The company's focus on transforming lives through medicines highlights their commitment to patients and their families. This suggests a vision centered around becoming a leading developer of therapies that significantly improve the quality of life for individuals affected by rare neurological conditions. Ovid's pipeline includes:

• OV815
• Soticlestat

These treatments are geared towards helping those affected by:

• Angelman syndrome
• Epilepsy

Ovid Therapeutics emphasizes collaboration, scientific rigor, and patient-centricity. These values likely shape their broader vision, pointing towards a future where they are recognized not only for their innovative therapies but also for their ethical and responsible approach to drug development. Some of the values Ovid holds include:

• Integrity
• Excellence
• Teamwork
• Innovation

In 2024, Ovid Therapeutics reported a net loss of $73.8 million, or $1.39 per share, compared to a net loss of $67.9 million, or $1.55 per share, for the year ended December 31, 2023. Research and development expenses were $43.4 million for the year ended December 31, 2024, compared to $43.8 million for the year ended December 31, 2023.

Ovid Therapeutics Inc. (OVID) Core Values of

While specific details on Ovid Therapeutics' mission statement, vision, and core values as of April 2025 are not directly available in the search results, we can still infer potential core values based on their activities and focus.

Based on available information, here are some possible core values for Company:

• Patient Focus: Prioritizing the needs and well-being of patients with rare neurological disorders.
• Innovation: Committing to the discovery and development of novel therapies.
• Collaboration: Working with researchers, clinicians, and patient communities.
• Integrity: Maintaining high ethical standards in research and development.

To gain a better understanding of Company's financial decisions and overall health, explore Breaking Down Ovid Therapeutics Inc. (OVID) Financial Health: Key Insights for Investors.